

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康集團

Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON 12 OCTOBER 2020**

The resolution as set out in the notice of the EGM was duly passed by way of a poll at the EGM held on 12 October 2020.

Reference is made to the circular (“**Circular**”) of Uni-Bio Science Group Limited (“**Company**”) dated 15 September 2020 in relation to the Variation of Terms to the Transaction Arrangements. Unless otherwise specified, capitalised terms used in this announcement shall have the same meaning as those defined in the Circular.

The Board is pleased to announce that the resolution as set out in the notice of the EGM was duly passed by way of a poll at the EGM held on 12 October 2020.

As at the date of the EGM, there were a total of 6,425,768,147 Shares in issue. To the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, save for (1) Mr. Leung and his associates, who together held 1,846,832,542 Shares; (2) Mr. Chen Dawei and his associates, who together held 155,094,438 Shares; and (3) Vital Vigour and its associates, who together held 865,040,000 Shares, each of which are required to abstain from voting on the resolution proposed at the EGM, no other Shareholder was required to abstain from voting on the resolutions proposed at the EGM. Accordingly, there were 3,558,801,167 Shares entitling the Shareholders to attend and vote on the resolution proposed at the EGM. Save as disclosed, none of the Shareholders was entitled to attend and abstain from voting in favour of the resolution proposed at the EGM according to Rule 13.40 of the Listing Rules. None of the Shareholders has stated their intention in the Circular to vote against the resolution proposed or to abstain from voting at the EGM.

The full text of the resolution was set out in the notice of the EGM dated 15 September 2020. The poll results of the resolution are as follows:

Ordinary resolution	Number of votes and percentage	
	For	Against
To approve, confirm and ratify the Variation of Terms and all other transactions contemplated thereunder, or incidental thereto including but not limited to the transactions contemplated under the WTGL SP Agreement as varied and supplemented by the First Supplemental Agreement, the Second Supplemental Agreement and the Third Supplemental Agreement (each as described and defined in the circular of the Company dated 15 September 2020) and to authorise the directors of the Company or a committee thereof to do all things and execute all documents as they may consider appropriate and desirable to effect and implement the Variation of Terms and the transactions contemplated thereunder.	530,127,935 (100%)	0 (0%)

As more than 50% of the votes were cast in favour of the resolution proposed at the EGM, the resolution was duly passed by the Shareholders as an ordinary resolution of the Company.

The Company's branch share registrar in Hong Kong, Tricor Abacus Limited, acted as the scrutineer for the vote-taking at the EGM.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 12 October 2020

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-chairman) and Mr. Zhao Zhi Gang; one non-executive Director, namely, Mr. Yau Kwok Wing Tony; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.

* For identification purpose only